A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.

被引：5
|
作者：
Edenfield, William Jeffery
Becerra, Carlos
Braiteh, Fadi S.
Spira, Alexander I.
Sullivan, Ryan J.
Panella, Timothy J.
Li, Wei
Huang, Janet
Li, Youzhi
Flaherty, Keith
Hitron, Matthew
Li, Chiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9553
引用
收藏
页数：5
相关论文
共 50 条
  • [1] A phase 1b study of napabucasin plus weekly paclitaxel in patients with advanced thymoma and thymic carcinoma
    Hitron, Matthew
    Spittler, Aaron John
    Cote, Gregory Michael
    Heist, Rebecca Suk
    Kossler, Kimiko
    Li, Wei
    Li, Youzhi
    Li, Chiang
    Loehrer, Patrick J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [3] A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer
    Shitara, Kohei
    Yodo, Yasuhide
    Iino, Shuichi
    [J]. IN VIVO, 2019, 33 (03): : 933 - 937
  • [4] A phase 1b study of napabucasin (NAPA) plus weekly paclitaxel (PTX) in patients (pts) with advanced thymoma and thymic carcinoma.
    Kalra, Maitri
    Cote, Gregory Michael
    Heist, Rebecca Suk
    Spittler, Aaron John
    Yu, Song
    Hitron, Matthew
    Loehrer, Patrick J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Phase II trial of weekly paclitaxel in patients with advanced melanoma
    Walker, L
    Schalch, H
    King, DM
    Dietrich, L
    Eastman, M
    Kwak, M
    Kim, K
    Albertini, MR
    [J]. MELANOMA RESEARCH, 2005, 15 (05) : 453 - 459
  • [6] A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
    Silk, Ann W.
    Curti, Brendan
    Bryan, Jennifer
    Saunders, Tracie
    Shih, Weichung
    Kane, Michael P.
    Hannon, Phoebe
    Fountain, Christopher
    Felcher, Jessica
    Zloza, Andrew
    Kaufman, Howard L.
    Mehnert, Janice M.
    McDermott, David F.
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] A Phase Ib/II Study of Cancer Sternness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.
    Becerra, Carlos
    Braiteh, Fadi S.
    Spira, Alexander I.
    Langleben, Adrian
    Panasci, Lawrence C.
    Vukelja, Svetislava J.
    Hinshaw, Ioana M.
    Goodwin, Rachel Anne
    Panella, Timothy J.
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients
    Rivkin, Saul Eugene
    Moon, James
    Iriarte, Desiree S.
    Bailey, Erik
    Sloan, Heather L.
    Goodman, Gary E.
    BonDurant, Amy E.
    Velijovich, Dan
    Wahl, Tanya
    Jiang, Peter
    Shah, Chirag A.
    Drescher, Charles
    Fer, Mehmet F.
    Kaplan, Henry G.
    Ellis, Erin D.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (02) : 325 - 333
  • [9] A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.
    Shaikh, Saba
    Zang, Yan
    Hanmer, Janel
    Wang, Hong
    Lin, Yan
    Davar, Diwakar
    Zarour, Hassane M.
    Kirkwood, John M.
    Najjar, Yana G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] A Phase Ib study of ruxolitinib plus gemcitabine ± nab-paclitaxel in patients with advanced solid tumors
    Bauer, Todd M.
    Patel, Manish R.
    Forero-Torres, Andres
    George, Thomas J., Jr.
    Assad, Albert
    Du, Yining
    Hurwitz, Herbert
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 2399 - 2407
12345